Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Exact Sciences Corporation (EXAS : NSDQ)
 
 • Company Description   
Exact Sciences Corporation is a molecular diagnostics company focused on the early detection and prevention of some of the deadliest forms of cancer. The company has developed an accurate, non-invasive, patient-friendly screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. The company is currently working on the development of additional tests for other types of cancer, with the goal of becoming a leader in cancer screening and diagnostics. Exact Sciences currently has two of the brands in cancer diagnostics, Cologuard and Oncotype DX. Cologuard Test: This is a non-invasive stool-based DNA screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. Oncotype DX: Genomic Health's first product, the 21-gene Oncotype DX breast cancer test is used to predict the likelihood of cancer recurrence, patient survival within 10 years of diagnosis and chemotherapy benefit for early-stage patients.

Number of Employees: 6,500

 
 • Price / Volume Information   
Yesterday's Closing Price: $50.55 Daily Weekly Monthly
20 Day Moving Average: 2,657,519 shares
Shares Outstanding: 175.95 (millions)
Market Capitalization: $8,894.02 (millions)
Beta: 1.23
52 Week High: $133.99
52 Week Low: $46.15
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -25.49% -18.35%
12 Week -31.81% -26.01%
Year To Date -35.05% -22.76%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
5505 ENDEAVOR LANE
-
MADISON,WI 53719
USA
ph: 608-535-8815
fax: 608-284-5701
meganjones@exactsciences.com http://www.exactsciences.com
 
 • General Corporate Information   
Officers
Kevin T. Conroy - President; Chief Executive Officer and Chairman
Jeffrey T. Elliott - Executive Vice President; Chief Financial Officer;
Paul Clancy - Director
Freda Lewis-Hall - Director
Pierre Jacquet - Director

Peer Information
Exact Sciences Corporation (CORR.)
Exact Sciences Corporation (RSPI)
Exact Sciences Corporation (CGXP)
Exact Sciences Corporation (BGEN)
Exact Sciences Corporation (GTBP)
Exact Sciences Corporation (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 30063P105
SIC: 8071
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 07/27/22
Share - Related Items
Shares Outstanding: 175.95
Most Recent Split Date: (:1)
Beta: 1.23
Market Capitalization: $8,894.02 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-1.08 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-4.26 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 07/27/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 2.73
Price/Cash Flow: -
Price / Sales: 4.80
EPS Growth
vs. Year Ago Period: -477.78%
vs. Previous Quarter: 18.75%
Sales Growth
vs. Year Ago Period: 21.01%
vs. Previous Quarter: 2.69%
ROE
03/31/22 - -21.82
12/31/21 - -16.95
09/30/21 - -12.06
ROA
03/31/22 - -11.23
12/31/21 - -8.89
09/30/21 - -6.21
Current Ratio
03/31/22 - 2.53
12/31/21 - 2.76
09/30/21 - 2.27
Quick Ratio
03/31/22 - 2.29
12/31/21 - 2.56
09/30/21 - 2.14
Operating Margin
03/31/22 - -40.26
12/31/21 - -33.71
09/30/21 - -22.10
Net Margin
03/31/22 - -40.26
12/31/21 - -33.71
09/30/21 - -46.14
Pre-Tax Margin
03/31/22 - -40.59
12/31/21 - -47.68
09/30/21 - -58.88
Book Value
03/31/22 - 18.52
12/31/21 - 19.66
09/30/21 - 20.11
Inventory Turnover
03/31/22 - 4.80
12/31/21 - 4.84
09/30/21 - 4.80
Debt-to-Equity
03/31/22 - 0.67
12/31/21 - 0.64
09/30/21 - 0.55
Debt-to-Capital
03/31/22 - 40.10
12/31/21 - 39.16
09/30/21 - 35.31
 

Powered by Zacks Investment Research ©